SPECIALIZED PRESS May 19, 2022 Not intended for U.S. and UK MediaBayer to present key data across oncology portfolio showcasing significant advances in cancer care at 2022 ASCO Annual MeetingRead more
SPECIALIZED PRESS May 19, 2022 Not intended for U.S. and UK MediaVerquvo™ (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fractionRead more
SPECIALIZED PRESS May 17, 2022 Not intended for U.S. and UK Media – 59th ERA Congress Paris & Virtual 2022:Bayer to present new Kerendia™ (finerenone) data from comprehensive clinical trial program in chronic kidney disease and type 2 diabetesRead more
May 13, 2022 New pharmaceutical production plantChancellor Olaf Scholz attends topping-out ceremony in LeverkusenRead more
May 10, 2022 First quarter at Bayer:Very good start to the year – strong sales and earnings growthRead more
SPECIALIZED PRESS May 3, 2022 Not intended for U.S. and UK MediaU.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)Read more
April 29, 2022 CEO Werner Baumann at the Annual Stockholders’ Meeting:“Bayer is on the right track”Read more
April 22, 2022 Bayer to create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology PlatformsRead more
SPECIALIZED PRESS April 22, 2022 Not intended for U.S. and UK MediaBayer submits application in China for additional indication of darolutamideRead more
.jpg)
